H.C. Wainwright analyst Ed Arce maintained a Buy rating on Paratek Pharmaceuticals (PRTK) today and set a price target of $27. The company’s shares closed yesterday at $3.09, close to its 52-week low of $2.87.
Arce commented:
“916-3963, Probability of success (POS) Risk-adj value Full value Rating NUZYRA – ABSSSI 100.0% $10.77 $10.77 Shares outstanding 32,535 S/O as of July 31, 2019.”
According to TipRanks.com, Arce is a 4-star analyst with an average return of 6.7% and a 34.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Paratek Pharmaceuticals with a $19 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $12.30 and a one-year low of $2.87. Currently, Paratek Pharmaceuticals has an average volume of 306.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
